Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
UBS analyst Vilas Abraham maintains Hercules Capital (NYSE:HTGC) with a Neutral and lowers the price target from $19 to $18.5.
Piper Sandler analyst Crispin Love maintains Hercules Capital (NYSE:HTGC) with a Overweight and lowers the price target from...
UniQure's AMT-130 gene therapy slowed Huntington's disease progression in a Phase 1/2 trial, supported by new $175 mill...
Term of current $50 million debt outstanding extended from January 2027 to October 2030Additional $100 million available subjec...
CGM commercial operations to transition from Ascensia Diabetes Care to SenseonicsBrian Hansen to be appointed Chief Commercial ...
JMP Securities analyst Devin Ryan maintains Hercules Capital (NYSE:HTGC) with a Market Outperform and raises the price targe...
Piper Sandler analyst Crispin Love maintains Hercules Capital (NYSE:HTGC) with a Overweight and raises the price target from...
